In Vitro Efficacy Testing Services for Endometriosis

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Endometriosis. Our services enable high-throughput evaluation of candidate compounds targeting key proteins, receptors, and pathways implicated in endometrial lesion growth and inflammation. Specifically, we focus on hormonal regulation, cellular proliferation, and inflammatory signaling, which are critical in the pathophysiology of Endometriosis. Our assays support the investigation of mechanisms such as estrogen metabolism, cell viability, and transcriptional activity associated with disease progression.

We offer a diverse suite of biochemical and cell-based assays to evaluate compound efficacy, mechanism of action, and target engagement in the context of Endometriosis. Our methods include luminescent, fluorescent, radiometric, RNA-based, and binding assays, providing comprehensive data on pharmacological profiles and disease-relevant endpoints.

ATP assay (at 1 mM): Quantifies cellular ATP levels as a marker of cell viability, proliferation, or cytotoxicity, relevant for assessing the impact of candidate therapies on endometrial cells.

Biolayer interferometry assay: Measures real-time biomolecular interactions and binding affinities between drug candidates and target proteins, facilitating the characterization of molecular mechanisms.

Bioluminescent assay: Detects cellular or enzymatic activity via light emission, offering sensitive readouts for target activity, gene expression, or reporter systems.

Chemiluminescent assay: Utilizes chemical reactions that emit light to quantify biomolecules, enzymatic activity, or signaling pathway modulation with high sensitivity.

Fluorescent assay: Employs fluorescence-based detection to monitor enzyme activities, cellular processes, or molecular interactions in live or fixed cells.

Luciferine/luciferase assay: Uses the luciferase enzyme system to report on gene expression or cellular events by measuring emitted light upon substrate conversion.

RNA assay: Quantifies gene expression changes following treatment, providing insights into transcriptional responses and pathway modulation relevant to Endometriosis.

Radioactivity assay: Measures incorporation or conversion of radiolabeled substrates to assess enzyme activities or receptor binding with high sensitivity and specificity.

[3H]-estrone as substrate: Utilizes tritiated estrone to study estrogen metabolism or enzyme activities involved in steroidogenesis, crucial for understanding hormonal regulation in Endometriosis.

[3H]-estrone sulfate as substrate: Applies radiolabeled estrone sulfate to investigate sulfatase activity or estrogenic pathway modulation, aiding in the profiling of hormonal interventions.

We measure a range of pharmacological parameters to comprehensively evaluate compound potency, efficacy, and binding characteristics. These parameters include EC-50, IC-50, Kd, and MIC, each providing critical information for lead optimization and candidate selection in drug development. By quantifying these values, we help guide decision-making in preclinical research.

EC-50: The concentration of a drug that produces 50% of its maximal effect, indicating compound potency and aiding in dose selection.

IC-50: The concentration of inhibitor required to reduce a specific biological activity by 50%, essential for comparing inhibitory strengths of candidate molecules.

Kd: The equilibrium dissociation constant that defines the affinity between a ligand and its target, critical for understanding binding interactions and drug-target engagement.

MIC: The minimum inhibitory concentration needed to prevent growth of a particular organism or cell type, useful for evaluating antimicrobial or antiproliferative activity.

Recommended In Vitro Efficacy Tests

C-X-C Motif Chemokine Ligand 8

C-X-C Motif Chemokine Ligand 8 (CXCL8) is implicated in endometriosis by promoting inflammation and lesion development. Measuring CXCL8 expression is crucial for evaluating drug efficacy and understanding disease mechanisms. Our testing service utilizes RNA assays to quantify CXCL8 levels, providing precise assessment of molecular changes. Minimum inhibitory concentration (MIC) is determined to evaluate drug potency against CXCL8-mediated pathways, supporting targeted endometriosis drug development.

Estrogen Receptor 1

Estrogen Receptor 1 (ER1) plays a pivotal role in endometriosis by mediating estrogen-driven cell proliferation. Our ER1 testing service supports drug development by quantifying compound activity using chemiluminescent, bioluminescent, and fluorescent assays. Determining EC-50 values enables precise assessment of a drug’s potency in modulating ER1, providing essential data for optimizing endometriosis therapeutics. This testing is crucial for identifying and characterizing effective ER1-targeted treatments.

Estrogen Receptor 2

Estrogen Receptor 2 (ERβ) plays a pivotal role in endometriosis pathogenesis by modulating inflammation and cell proliferation. Testing ERβ is crucial for identifying drug candidates targeting estrogen signaling. Our service utilizes quantitative PCR, immunohistochemistry, and ligand-binding assays to assess ERβ expression and activity. Main parameters include receptor expression levels, localization, and functional response to drug candidates, providing actionable insights for endometriosis drug development.

Hydroxysteroid 17-Beta Dehydrogenase 1

Hydroxysteroid 17-Beta Dehydrogenase 1 (HSD17B1) regulates estradiol production, contributing to estrogen-driven endometriosis progression. Testing HSD17B1 inhibitors is crucial for developing targeted endometriosis therapies. Our assay employs [3H]-estrone as the substrate to assess compound potency, with IC₅₀ values as the primary readout for inhibitory activity. This service enables efficient screening and optimization of drug candidates targeting HSD17B1.

Interleukin 1 Receptor Associated Kinase 4

Interleukin 1 Receptor Associated Kinase 4 (IRAK4) mediates inflammatory signaling implicated in endometriosis pathogenesis. IRAK4 testing is crucial for evaluating candidate drugs targeting this pathway. Our service utilizes an ATP assay (1 mM) to assess compound activity, determining the half-maximal inhibitory concentration (IC-50). This enables precise measurement of drug efficacy against IRAK4, supporting the development of targeted therapies for endometriosis.

Progesterone Receptor

Progesterone Receptor (PR) plays a critical role in endometriosis pathogenesis and response to therapy. Accurate PR testing is essential for drug development, enabling assessment of drug efficacy and receptor modulation. Our service offers chemiluminescent and radioactivity assays to quantify PR activity, providing key parameters such as EC-50 and IC-50 values. These metrics inform potency and inhibitory effects, supporting targeted endometriosis treatment strategies.

Prolactin Receptor

Prolactin Receptor (PRLR) is implicated in endometriosis pathogenesis by mediating proliferative and inflammatory signaling. PRLR testing is crucial for evaluating drug candidates targeting this pathway. Our service employs luciferin/luciferase and biolayer interferometry assays to assess compound efficacy and receptor binding. Key parameters measured include IC₅₀ (half-maximal inhibitory concentration) for functional inhibition and Kd (dissociation constant) for binding affinity, providing comprehensive data to advance endometriosis drug development.

Steroid Sulfatase

Steroid sulfatase plays a key role in endometriosis by converting inactive steroid sulfates into active estrogens, promoting lesion growth. Testing its activity is crucial for evaluating drug candidates targeting this pathway. Our assay utilizes [3H]-estrone sulfate as a substrate to precisely measure enzyme inhibition. The primary parameter assessed is IC₅₀, indicating the compound concentration required to inhibit steroid sulfatase activity by 50%, aiding in drug efficacy assessment.